OCTAPLASLG infusioonilahus Eesti - eesti - Ravimiamet

octaplaslg infusioonilahus

octapharma (ip) - inimvereplasma proteiinid - infusioonilahus - 70mg 1ml 200ml 10tk; 70mg 1ml 200ml 1tk

VARIVAX süstesuspensiooni pulber ja lahusti süstlis Eesti - eesti - Ravimiamet

varivax süstesuspensiooni pulber ja lahusti süstlis

merck sharp & dohme b.v. - tuulerõugete viirus, elus, nõrgestatud - süstesuspensiooni pulber ja lahusti süstlis - 1annus 0.5ml 0.5ml 1tk; 0.5ml 10tk; 0.5ml 1tk

Comirnaty Euroopa Liit - eesti - EMA (European Medicines Agency)

comirnaty

biontech manufacturing gmbh - single-stranded, 5’-capped messenger rna produced using a cell-free in vitro transcription from the corresponding dna templates, encoding the viral spike (s) protein of sars-cov-2 - covid-19 virus infection - vaktsiinid - comirnaty 30 micrograms/dose concentrate for dispersion for injection is indicated for active immunisation to prevent covid-19 caused by sars-cov-2, in individuals 12 years of age and older.  comirnaty 30 micrograms/dose dispersion for injection is indicated for active immunisation to prevent covid-19 caused by sars-cov-2, in individuals 12 years of age and older.  comirnaty 10 micrograms/dose concentrate for dispersion for injection is indicated for active immunisation to prevent covid-19 caused by sars-cov-2, in children aged 5 to 11 years.  comirnaty 3 micrograms/dose concentrate for dispersion for injection is indicated for active immunisation to prevent covid-19 caused by sars-cov-2, in infants and children aged 6 months to 4 years.  comirnaty original/omicron ba. 1 (15/15 micrograms)/dose dispersion for injection is indicated for active immunisation to prevent covid-19 caused by sars-cov-2, in individuals 12 years of age and older who have previously received at least a primary vaccination course against covid-19. comirnaty original/omicron ba. 4-5 (15/15 micrograms)/dose dispersion for injection is indicated for active immunisation to prevent covid-19 caused by sars-cov-2, in individuals 12 years of age and older. comirnaty original/omicron ba. 4-5 (5/5 micrograms)/dose concentrate for dispersion for injection is indicated for active immunisation to prevent covid-19 caused by sars-cov-2, in children aged 5 to 11 years. comirnaty original/omicron ba. 4-5 (5/5 micrograms)/dose dispersion for injection is indicated for active immunisation to prevent covid-19 caused by sars-cov-2, in children aged 5 to 11 years.  comirnaty original/omicron ba. 4-5 (1. 5/1. 5 micrograms)/dose concentrate for dispersion for injection is indicated for active immunisation to prevent covid-19 caused by sars-cov-2, in infants and children aged 6 months to 4 years.  comirnaty omicron xbb. 5 30 micrograms/dose dispersion for injection is indicated for active immunisation to prevent covid-19 caused by sars-cov-2, in individuals 12 years of age and older. comirnaty omicron xbb. 5 10 micrograms/dose concentrate for dispersion for injection is indicated for active immunisation to prevent covid-19 caused by sars-cov-2, in children aged 5 to 11 years. comirnaty omicron xbb. 5 10 micrograms/dose dispersion for injection is indicated for active immunisation to prevent covid-19 caused by sars-cov-2, in children aged 5 to 11 years. comirnaty omicron xbb. 5 3 micrograms/dose concentrate for dispersion for injection is indicated for active immunisation to prevent covid-19 caused by sars-cov-2, in infants and children aged 6 months to 4 years. kasutamist see vaktsiin peaks olema kooskõlas ametlike soovitustega.

Tobi Podhaler Euroopa Liit - eesti - EMA (European Medicines Agency)

tobi podhaler

viatris healthcare limited - tobramycin - cystic fibrosis; respiratory tract infections - antibacterials süsteemseks kasutamiseks, - tobi podhaler on näidustatud kroonilise pulmonaalse infektsiooni tõttu fibroosiga täiskasvanutel ja 6-aastastel lastel pärssivat ravi tsüstilise fibroosiga. vt lõigud 4. 4 ja 5. 1 andmete kohta erinevates vanuserühmades. tuleks arvesse võtta ametlikke juhiseid sobiva kasutada antibakteriaalseid aineid.

Carbaglu Euroopa Liit - eesti - EMA (European Medicines Agency)

carbaglu

recordati rare diseases - karglumhape - amino acid metabolism, inborn errors; propionic acidemia - muud alimentary seedetrakti ja ainevahetust tooted, - carbaglu on näidustatud ravi:hyperammonaemia tõttu n-acetylglutamate-synthase esmane puudus;hyperammonaemia tõttu isovaleric acidaemia;hyperammonaemia tõttu methymalonic acidaemia;hyperammonaemia tõttu propioonhappe acidaemia.

DUOFILM nahalahus Eesti - eesti - Ravimiamet

duofilm nahalahus

stada arzneimittel ag - salitsüülhape+piimhape - nahalahus - 167mg+150mg 1ml 15ml 1tk

DUOFILM nahalahus Eesti - eesti - Ravimiamet

duofilm nahalahus

ideal trade links uab - salitsüülhape+piimhape - nahalahus - 167mg+150mg 1ml 15ml 1tk

ONDANSETRON KALCEKS süste-/infusioonilahus Eesti - eesti - Ravimiamet

ondansetron kalceks süste-/infusioonilahus

kalceks as - ondansetroon - süste-/infusioonilahus - 2mg 1ml 2ml 25tk; 2mg 1ml 2ml 10tk; 2mg 1ml 2ml 5tk; 2mg 1ml 4ml 10tk

DEXAMETHASONE KALCEKS süste-/infusioonilahus Eesti - eesti - Ravimiamet

dexamethasone kalceks süste-/infusioonilahus

kalceks as - deksametasoon - süste-/infusioonilahus - 4mg 1ml 2ml 5tk; 4mg 1ml 2ml 10tk

ESKETEX süste-/infusioonilahus Eesti - eesti - Ravimiamet

esketex süste-/infusioonilahus

kalceks as - esketamiin - süste-/infusioonilahus - 25mg 1ml 10ml 10tk; 25mg 1ml 10ml 5tk; 25mg 1ml 2ml 10tk; 25mg 1ml 2ml 5tk